Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells

Abstract Backgrounds Tamoxifen is typically used to treat patients with estrogen receptor alpha (ERα)-positive breast cancer. However, 30% of these patients gain acquired resistance to tamoxifen during or after tamoxifen treatment. As a Ras modulator, Nogo-B receptor (NgBR) is required for tumorigen...

Full description

Bibliographic Details
Main Authors: Pin Gao, Xiang Wang, Ying Jin, Wenquan Hu, Yajun Duan, Aiping Shi, Ye Du, Dong Song, Ming Yang, Sijie Li, Bing Han, Gang Zhao, Hongquan Zhang, Zhimin Fan, Qing Robert Miao
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Breast Cancer Research
Subjects:
Nogo-B receptor
Survivin
Tamoxifen
Estrogen receptor
Breast cancer
Online Access:http://link.springer.com/article/10.1186/s13058-018-1028-5

Internet

http://link.springer.com/article/10.1186/s13058-018-1028-5

Similar Items